Caplin Point Laboratories
ICICI Direct
Broker Research reports: Buy reports
for all stocks
- This broker has downgraded this stock from it's previous report. (eg. - Buy->Hold)
- Broker has maintained previous recommendation but reduced share price target.
- This broker has upgraded this stock from it's previous report.(eg. - Sell->Hold)
- Broker has maintained previous recommendation but increased share price target.
RESEARCH REPORTS ALERTS
Load latest
Google or static link led you to an intermediate page.
- All Recent
- Upside
- Buy
- Sell
- Recent Upgrades
- Recent Downgrades
- IPO
- Sector Updates
- Most Recent
- Top Upside
Click on any table column to sort reports by date, stock name, broker, price, target, upside or recommendation.
| Summary | Date | Stock | Author | LTP | Target | Price at reco (Change since reco%) |
Upside(%) | Type | Report | Discuss | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 28 May 2023 | Caplin Point Labs |
ICICI Direct
|
2036.90 | 900.00 | 736.35 (176.62%) | Target met |
Buy
|
||||
| 28 May 2023 | Mahindra & Mahindra |
ICICI Direct
|
3396.50 | 1600.00 | 1281.85 (164.97%) | Target met |
Buy
|
||||
| 27 May 2023 | Healthcare Global |
Prabhudas Lilladhar
|
647.40 | 375.00 | 293.75 (120.39%) | Target met |
Buy
|
||||
| 27 May 2023 | Birla Corporation |
Axis Direct
|
1237.30 | 1111.00 | 1010.15 (22.49%) | Target met |
Buy
|
||||
| 27 May 2023 | Sun Pharmaceutical |
Motilal Oswal
|
1586.70 | 1160.00 | 969.90 (63.59%) | Target met |
Buy
|
||||
| 27 May 2023 | Samvardhana Motherson |
Motilal Oswal
|
105.66 | 100.00 | 80.75 (30.85%) | Target met |
Buy
|
||||
| 27 May 2023 | Mahindra & Mahindra |
Motilal Oswal
|
3396.50 | 1500.00 | 1281.85 (164.97%) | Target met |
Buy
|
||||
| 27 May 2023 | Grasim Industries |
Motilal Oswal
|
2746.80 | 1940.00 | 1688.30 (62.70%) | Target met |
Buy
|
||||
| 27 May 2023 | Ashok Leyland |
BOB Capital Markets Ltd.
|
141.93 | 184.00 | 145.50 (-2.45%) | Target met |
Buy
|
||||
| 27 May 2023 | Sun Pharmaceutical |
ICICI Securities Limited
|
1586.70 | 1160.00 | 969.90 (63.59%) | Target met |
Buy
|
Specialty portfolio is amplifying margins
ICICI Securities Limited
Sun Pharmaceutical’s (Sun) Q4FY23 performance was decent, aided by traction in specialty portfolio, India branded and launch of Revlimid in the US. Specialty business sales contribution had increased to 16.6% in FY23 (14% in FY22) and key assets like Ilumya, Winlevi and Cequa will likely improve the share to 21% by FY25E.
|
|||
|
more
loading
|
|||||||||||
* Please note that subscribers can download a maximum of 300 reports a month and 70 reports everyday.